NCT07745426RecruitingPhase 2
Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 4 Aug 2026
Brief summary (registry, in English)
This study will be a randomized controlled parallel study that will be conducted on 66 patients with active rheumatoid arthritis who will be diagnosed with RA according to American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR, 2010). The patients will be recruited from Outpatient Clinic of Rheumatology, Physical Medicine, Rheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt. The study duration will be 3 months. The patients will be randomized into three groups: \- Group 1 (control group): will include 22 patients who will receive the conventional therapy for RA for 3 months. \- Group 2 (diosmin group): will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months. \- Group 3 (rebamipide group): will include 22 patients who will receive the conventional therapy for RA plus 100 mg rebamipide three times daily for 3 months.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- First submitted
- 29 Jul 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 1 Aug 2027
- Lead sponsor
- Tanta University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07745426
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 66
- From 1 Aug 2026 to the primary completion date, 1 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving biological DMARDs or targeted synthetic DMARDs.
- Patients with bleeding disorders, receiving warfarin or other anticoagulants.
- Patients receiving antioxidants.
Other illness
- Patients with other inflammatory/autoimmune diseases, active infection, or malignancies.
- Patients with hypersensitivity to study medications.
Other
- Pregnant and lactating females.
- Patients with renal and hepatic dysfunction.
Who the study is looking for
- Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR). i.e.,28 joints disease activity score (DAS-28) \>2.6.
- Both sexes.
- Age ranges between 18 and 70 years old.
- Patients receiving conventional DMARDs
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Pharmacy, Tanta University Coordinator of this site? Confirm its status | Tanta | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.